The decision on adjuvant treatment for breast cancer patients is based on risk assessment using clinicopathological criteria, such as patient age, menopausal status, axillary lymph node status, tumor size, tumor grade, estrogen receptor (ER)/progesterone receptor (PgR) expression, HER2 status, and Ki67 score. Here, ESR1 is linked to neoplasm.